Search Results

Press Releases

Xentria Launches Xturnpoint to Fuel Early-Stage Therapeutic Innovation, Expands Headquarters to Support Growth

May 23, 2025

·

3 min read

Press Releases

Xentria Advances XTMAB16 Study in Pulmonary Sarcoidosis with Completed Enrollment and Key Conference Selections

March 19, 2025

·

5 min read

Press Releases

Expanding Horizons: Xentria Achieves Milestone Success with Biosimilar Development

January 8, 2025

·

3 min read

BioMidwest

Xentria’s XTMAB-16 Receives Orphan Drug Designation From European Medicines Agency as First Patient is Enrolled in Study

Xentria announces major milestone of first patient enrolled in The XTMAB16 Study evaluating TNFα inhibitor for the treatment of sarcoidosis.

November 15, 2023

·

5 min read

Press Releases

Xentria Announces Exclusive Licensing Agreement with New York University to Advance a Disease-Modifying Cardiovascular Therapy Globally

December 19, 2024

·

2 min read

BioMidwest

Xentria Announces Peer Reviewed Publication of Biosimulation Model in Frontiers in Pharmacology Journal

Xentria Announces Peer Reviewed Publication of Biosimulation Model in Frontiers in Pharmacology Journal.

March 21, 2023

·

6 min read

BioMidwest

Xentria and Meitheal Pharmaceuticals Announce Exclusive Licensing Agreement for XTMAB-16 in North America

Xentria Inc. and Meitheal Pharmaceuticals, Inc. announced an exclusive multi-year licensing agreement to commercialize its lead candidate, and novel biologic, XTMAB-16 for pulmonary sarcoidosis in North America.

June 27, 2023

·

6 min read

BioMidwest

Xentria Announces $25 Million Equity Financing Round to Advance Pipeline and Execute on Growth Strategy

Xentria Inc. announced a $25 million growth equity funding round approved by its Board of Directors and the opening of a new corporate headquarters.

October 18, 2022

·

3 min read

Business

Xentria Appoints Lead Scientific Advisor and Chief Operating Officer

Xentria Inc., a biotech company focused on developing novel therapeutics to address unmet clinical needs, made key leadership appointments, naming Dr. Robert Baughman as Lead Scientific Advisor and Kirsten Anderson as Chief Operating Officer.

August 4, 2022

·

4 min read

BioMidwest

Xentria Announces Initial Findings Showing Novel Biologic XTMAB-16’s Potential to Reduce Sarcoidosis Granuloma

Xentria Inc., a biotech company focused on developing novel biologics to address unmet clinical needs, presented its first set of data showing its novel biologic, XTMAB-16, has the potential to reduce the formation of sarcoidosis granulomas.

June 23, 2022

·

4 min read